Previous Close | 16.66 |
Open | 16.65 |
Bid | 16.96 x 50000 |
Ask | 17.05 x 194200 |
Day's Range | 16.47 - 17.08 |
52 Week Range | 12.39 - 17.27 |
Volume | |
Avg. Volume | 3,514,997 |
Market Cap | 16.155B |
Beta (5Y Monthly) | 0.48 |
PE Ratio (TTM) | 14.82 |
EPS (TTM) | 1.15 |
Earnings Date | Jul 24, 2024 - Jul 29, 2024 |
Forward Dividend & Yield | 0.78 (4.73%) |
Ex-Dividend Date | Mar 22, 2024 |
1y Target Est | 16.41 |
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, provides an update on the initiative to divest "non-core" assets and increase focus on its core brands and businesses.
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the first quarter of 2024. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise mentioned.
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company") today announced that it will report its First Quarter 2024 Earnings Results on Wednesday, April 24, 2024, after the Mexican Stock Exchange (BMV) close. The company also announced that it will hold a conference call on Thursday, April 25, 2024, at 1 p.m. ET to discuss its quarterly financial results.